baber/WOPTO huggingface dataset:
Patent NZ-568139-A (NZ)
Title: Apparatus for forming hole in organ such as heart for apicoaortic conduit implant, with sequencing means to control retractor expansion
Inventor: BEANE RICHARD M
IPC: A61B17/11
Filed: 2006-10-16
Abstract: The disclosure relates to an apparatus and method for forming a hole in a wall of a hollow organ. The applicator includes a hole forming element for forming a hole in the wall of the organ, a positioning means (300) for positioning the hole forming element, and a retractor element. In addition, the applicator includes a sequencing means for coordinating the relative movement of the retractor element and the hole forming element in a sequential manner to thereby carry out a procedure for forming a hole in the wall of the hollow organ. The sequencing means may further include a safety latch element operatively coupled to the retracting means and the hole forming element. The safety latch of the invention prevents damage to the internal surface of the organ during the formation of the hole.
Patent NZ-568327-A (NZ)
Title: Display rack for spectacles
Inventor: COOPER DAN
Filed: 2008-05-15
Abstract: A rack for displaying spectacles is disclosed. The rack comprises one or more panels (2), each panel comprising a sheet of material containing a plurality of apertures (3). The apertures are arranged to support pairs of spectacles (15) by providing sets of three apertures being arranged as a group having one lower aperture that bisects a pair of upper apertures, at least some of the lower apertures each retaining a support member (10) extending outwards from the plane of the panels. The upper apertures are adapted to each receive a sidepiece of a pair of spectacles and the support member is adapted to receive, in an indent (11), the nosepiece of a pair of spectacles. The plurality of apertures are arranged in a regular array consisting of a plurality of vertical columns being alternately offset against each other, such that the columns are approximately an equal distance apart.
Patent NZ-568907-A (NZ)
Title: Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
Inventor: KOJIMA RYOTARO
IPC: A61K45/00
Filed: 2007-02-05
Abstract: Disclosed herein is the use of 2-amino-2[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or a pharmaceutically acceptable salt or a hydrate thereof in the manufacture of a medicament for the treatment of an inflammatory bowel disease; such as Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer, or pouchitis. The medicament may also be formulated for administration with at least one further therapeutic agent for an inflammatory bowel disease.
Patent NZ-569188-A (NZ)
Title: Modular convection air source energy recovery
Inventor: HILL ANTHONY STEPHEN
Filed: 2008-06-18
Abstract: A modular system for recovering low-grade waste solar generated energy in a ceiling space is disclosed. The system uses a vapour compression cycle for transferring roof space air heat to a thermal water storage vessel. A plenum duct (5) warm air scavenging reservoir encloses a series of modular evaporator panels (4) interconnected in parallel to refrigerant header tubes (3) and refrigerator lines in an endless loop through a compressor (2) encapsulated in the base of the vessel and a heat exchanger (8) immersed in the water.
Patent NZ-570122-A (NZ)
Title: A portable lighting device with a visible flashing function
Inventor: WEST STACEY H
IPC: F21Y101/00
Filed: 2007-02-05
Abstract: A portable lighting device is disclosed. The portable lighting device comprises: a main power circuit (400), a power control circuit (700), and a microprocessor. The main power circuit (400) includes a power source (60), a light source (59), and an electronic power switch (702) to regulate current flow through the main power circuit (400) in response to a voltage. The power control circuit (700) is electrically coupled to the electronic power switch (702) to provide the voltage in response to a control signal. The microprocessor includes an output coupled to the power control circuit (700), where the microprocessor provides the control signal to the power control circuit (700), and the control signal is cycled with a sufficient duration to provide a visible flashing function through the light source (59) of the portable lighting device.
Patent NZ-573371-A (NZ)
Title: Indoles as 5-ht6 modulators
Inventor: JOHANSSON GARY
IPC: C07D209/14
Filed: 2007-07-03
Abstract: Disclosed herein are indole compounds of formula (I) wherein substituents are as defined within the specification. Such compounds are useful in treatment of pain, neurodegenerative disorders, type II diabetes, reduing bodyweight of reducing body weight gain, modulation of 5-HT6 receptor activity and disorders of the central nervous system such as anxiety, depression, panic attacks, memory disorders, cognitive disorders, epilepsy, sleep disorders, migraine, anorexia, bulimia, binge eating disorders, obsessive compulsive disorders, psychoses, Alzheimer's disease, Parkinson's disease, Huntington's chorea, schizophrenia, attention deficit hyperactive disorder and withdrawal from drug abuse. Also disclosed are pharmaceutical compositions comprising a compound of formula (I), as well as processes for their preparation.
Patent NZ-576058-A (NZ)
Title: Hdac inhibitors
Inventor: DAVIDSON ALAN HORNSBY
IPC: A61K31/223
Filed: 2007-09-14
Abstract: A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof e.g. Cyclopentyl (2S)-cyclohexyl({ 4-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]benzyl} amino)acetate wherein A, B and D independently represent =C- or =N-; R1 is an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, Alk1 and Alk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-ORECIEVED ), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-,-NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4- wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; and z is 0 or 1; Furthermore, also disclosed is a pharmaceutical composition comprising a compound of formula (I), and the use of compound of formula (I) in the preparation of a medicament for the treatment of cancer cell proliferation, Huntington's disease, Alzheimer's disease, or rheumatoid arthritis.
Patent NZ-580982-A (NZ)
Title: Methods of treatment using intravenous formulations comprising temozolomide
Inventor: ABUTARIF MALAZ
IPC: A61K31/4188
Filed: 2008-05-07
Abstract: Disclosed is the use of temozolomide or a pharmaceutically acceptable salt thereof for the manufacture of a formulation for the treatment of a proliferative disorder in a patient, wherein the treatment comprises administering a dose of 150 mg/m2 of temozolomide to the patient by intravenous infusion over a period of about 90 minutes, wherein the administration achieves an arithmetic maximum plasma concentration (Cmax) of temozolomide in the range of about 5.5 to about 10.6 ìg/mL and an arithmetic maximum plasma concentration (Cmax) of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) in the range of about 137 to about 916 ng/mL.
Patent NZ-585054-A (NZ)
Title: Key management for secure communication
Inventor: CHENG YI
IPC: H04L9/08
Filed: 2007-11-30
Abstract: 585054 Disclosed is a method for establishing secure communication between communication devices in a communications network. A first communication device transmits a request to a first key management server (KMS) apparatus and in response to the request, the first KMS apparatus transmits keying information and a voucher with an identifier for retrieving the keying information. The first communication device receives this keying information and creates a session with a second communication device which is separate from the first KMS apparatus. Creating the session with the second communication device includes transmitting a session invitation message that comprises the voucher.
Patent NZ-587868-A (NZ)
Title: A flush valve where the float has bleed openings in an end wall and unitary baffles extending above the bleed openings.
Inventor: DENZIN PETER W
IPC: E03D1/35
Filed: 2006-11-03
Abstract: A flush valve (26) for controlling the flow of water from a toilet tank through an outlet to a toilet bowl comprising a valve body (28) and a float (30) movable with respect to the valve body (28). The float (30) mounts a seal (32) for sealing against the valve seat and has a hollow body which extends along a longitudinal axis. An end wall (62) extends across the end of the float at an angle to the axis with at least one bleed opening (70) which defines a passage into the hollow body of the float. At least one baffle is formed as a unitary part of the end wall and is spaced longitudinally above the at least one bleed opening (70).
Patent NZ-591033-A (NZ)
Title: Ethylene production from acetic acid utilizing dual reaction zone process
Inventor: JOHNSTON VICTOR J
IPC: C07C1/207
Filed: 2009-07-20
Abstract: Disclosed is a process for selective formation of ethylene from acetic acid comprising: contacting a feed stream containing acetic acid and hydrogen in vapour phase at a temperature of 200 degrees to 375 degrees Celsius with a first catalytic composition including a hydrogenating catalyst containing a metal selected from the group consisting of copper, nickel, aluminium, chromium, zinc, palladium or a mixture thereof on a support in a first reaction zone to form an intermediate hydrogenated mixture; and reacting said intermediate hydrogenated mixture over a second catalytic composition which includes a dehydrating catalyst comprising a zeolite catalyst selected from the group consisting of H-mordenite, ZSM-5, a zeolite X and a zeolite Y in a second reaction zone to form ethylene. In particular the hydrogenating catalyst is selected from the group consisting of copper on an iron oxide support or copper-aluminium catalyst on a support. The intermediate hydrogenated mixture comprising acetic acid, ethanol and ethyl acetate.
Patent NZ-592168-A (NZ)
Title: Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
Inventor: LEDOUSSAL BENOIT
IPC: A61K31/439
Filed: 2009-07-29
Abstract: 592168 Disclosed are compounds of formula (I), e.g. trans 8-(aminomethyl)-2-(3-amino-propyl-carbamoyl)-4,8-dihydro-S-(sulphooxy)-4,7-methano-7H-pyrazolo[3,4-e][1,3]diazepin-6(5H)-one in their possible enantiomeric or diasteroisomeric forms, or mixtures in which the variables are defined in the specification in the free form and in the form of zwitterions and salts with pharmaceutically acceptable bases and mineral or organic acids for treating bacterial infection.
Patent NZ-595022-A (NZ)
Title: Stable probiotic granulate, and method for preparing same
Inventor: HIOLLE AMELIE
IPC: A23K1/00
Filed: 2010-03-09
Abstract: 595022 Disclosed is a granulation method comprising steps of: a- incorporating, into a nutritional mixture suitable for the intended application, a probiotic composition 5 A consisting of: - from 2 to 30% by weight of the total weight of the composition, of a probiotic yeast in a dry form agglomerated into spherules having a dry matter DM content of between 93% and 98% and a median diameter d of the spherules of between 800 ?m and 1200 ?m, and - from 70% to 98% by weight of the total weight of the composition, of a nutritional supplement comprising at least one constituent chosen from vitamins, trace elements, amino acids, and other additives intended for animal or human food and/or health, b- injecting steam at a temperature of between 60 degree C and 85 degree C at pressure values ranging from 0.5 to 4 bar into the mixture obtained in step a, c- granulating the mixture obtained in step b by pressing said mixture at a temperature of between 70 degree C and 92 degree C in order to produce granules having a diameter D of between 2 and 6 mm, and d- cooling the granules obtained in step c, wherein the temperature T of the granulating step, the diameter of the granules D, the dry matter DM content, and the median diameter d of the spherules are set so as to satisfy the following equation: X = -196.482 - 0.023 d + 2.256 (DM) - 14.793 T+ 3.046 D + 6.25.10-5 d (DM) + 0.001 d.T + 5.6310-5 d.T + 0.167(DM) .T - 0.036 (DM) .T - 0.023D.T + 4.06.10-6 d² + 0.003 T² wherein X is the yeast lost after granulation (log CFU/g initially - log CFU/g after granulation), and X is less than 1 log CFU/g of granular food.
Patent NZ-596229-A (NZ)
Title: Inhibitors of the renal outer medullary potassium channel
Inventor: ZHU YUPING
IPC: A61K31/495
Filed: 2010-04-29
Abstract: 596229 Provided are compounds of formula I, where R5, R6, Z1 and Z2 are as described in the specification. Examples of preferred compounds include 6-({ 4-[2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl)piperazin-1-yl} methyl)-8,9-dihydro-1H-furo[3,4-f]isochromen-3(6H)-one, 5,5'-{ piperazine-1,4-diylbis[(1R)-1-hydroxyethane-2,1-diyl]bis(4-methyl-2-benzofuran-1-(3H)-one) and 6-[(1S)-1-hydroxy-2-{ 4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl} ethyl]pyridine-3-carbonitrile. The compounds inhibit renal outer medullary potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics, natriuretics and in the therapy of cardiovascular diseases such as hypertension, and disorders resulting from excessive salt and water retention.
Patent NZ-598470-A (NZ)
Title: A milker unit backflushing system for cleaning a dairy animal milker unit after milking, wherein the backflushing system comprises a safety valve located downstream of the milker unit which moves between a milking position and a backflushing position
Inventor: TORGERSON KEVIN L
IPC: A01J7/02
Filed: 2010-09-03
Abstract: 598470 A system for backflush cleaning a dairy animal milker unit (40) and applying teat dip to dairy animals is disclosed. The system includes a main control (26), an air supply (25), a water supply (29), a backflush fluid supply (28), a stall control (36) for receiving the air, and a safety valve (60). The safety valve comprises a backflush piston for movement between a milking position and a backflush position. The safety valve is adjacent to a downstream portion of the milker unit. The safety valve allows milk flow from the milker unit when in the milking position and allows backflush fluid flow to the milker unit when in the backflush position. A teat dip applicator system is also disclosed, wherein the safety valve further comprises a dip valve piston which controls the flow of dip to the milker unit.
Patent NZ-605966-A (NZ)
Title: Animal models and therapeutic molecules
Inventor: BRADLEY ALLAN
IPC: C12N15/90
Filed: 2011-01-07
Abstract: Disclosed is a mouse whose genome comprises: (a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions upstream of a mouse constant region; (b) one or more human Ig light chain kappa V regions and one or more human Ig light chain kappa J regions upstream of a mouse kappa constant region and optionally one or more human Ig light chain lambda V regions and one or more human Ig light chain lambda J regions upstream of a mouse lambda constant region; wherein the mouse is able to produce a repertoire of chimaeric antibodies, or chimaeric heavy chains and chimaeric light chains, having a mouse constant region and a human variable region; wherein the mouse genome comprises a chimaeric antibody chain locus, the locus encoding a chimaeric heavy chain; and wherein the locus comprises a mouse constant region nucleotide sequence and a rearranged VDJ nucleotide sequence produced by in vivo rearrangement of a human V region, a human D region and a human J region; - the V region being a V1-3 segment; and - the mouse expressing more V1-3 JH4 or V1-3 JH6 antibodies than any of, individually, V1-3 JH1, V1-3 JH2, V1-3 JH3 or V1-3 JH5 antibodies.
Patent NZ-613922-A (NZ)
Title: Device for electrically braking a drive shaft
Inventor: PANSERI ANNE SOPHIE
IPC: F16D65/16
Filed: 2012-02-08
Abstract: Disclosed is a device for electrical braking of a drive shaft (5) which is guided by a fixed frame (6). The device enables precise positioning of electric jaws (7) with respect to a brake disc (3). The device includes a brake disc (3); a braking element (2); electric jaws (7); at least one sliding block (8) and fastening means (4). The brake disc (3) is fixed to one end of the drive shaft (5). The brake element (2) is formed by the electric jaws (7) and the at least one sliding block (8). The electric jaws (7) and sliding block (8) are mounted in the proximity of the brake disc (3) such that the brake disc (3) passes at least partially through the electric jaws (7) and sliding block (8). Fastening means (4) fasten the electric jaws (7) and sliding block (8) to the frame (6) while providing the electric jaws (7) and sliding block (8) with degrees of freedom. Degrees of freedom are obtained by the combination of different connections which include a “flat plane contact”, “point contact” and “annular linear contact”. The “flat plane contact”, “point contact” and “annular linear contact” compensate for the misalignments and defects in the shape of the brake disc (3) when driven in rotation. The “flat plane contact” is formed by mounting the at least one sliding block (8) to a plate (10). The “point contact” is formed by a first pin fixed to the frame. The “annular linear contact” is formed by a second pin (14) fixed to the frame (6) and a swivel joint (16) which is placed around the second pin (14).
Patent NZ-615570-A (NZ)
Title: A pallet and method of assembling a pallet
Inventor: CLINT PAUL MOKA
IPC: B65D19/26
Filed: 2013-09-16
Abstract: 615570 A pallet is formed from a deck with tabs, and parallel first bearers and parallel second bearers arranged transversely to the first bearers. The first bearers have first locking members which are coupled to notches of the second bearers to form an interlocking array of bearers. The first bearers also have second locking members coupled with tabs of the deck so as to couple the array of bearers to the deck.
Patent NZ-623755-A (NZ)
Title: A tube module
Inventor: HÖGLUND KASPER
IPC: F28F1/42
Filed: 2012-10-31
Abstract: A tubular heat exchange module comprising at least two concentric tubes (1, 2) with spiral features, wherein tube (2) is coaxially arranged inside tube (1) and each tube has a maximum diameter and a minimum diameter, the maximum diameter of tube (2) is larger than the minimum diameter of tube (1). A flow path (3) for fluids is defined between tube (1) and tube (2). The disclosure relates further to a tubular flow module system and use of the tubular flow module.
Patent NZ-623803-A (NZ)
Title: Indoor unit for air-conditioning apparatus
Inventor: YAMAGUCHI KOUJI
IPC: F24F13/32
Filed: 2014-04-14
Abstract: An indoor air conditioner with a stand attached to a base of the ac to form a flat installation surface of a housing to be placed on a floor surface by offsetting a level difference formed by a step in the base. The stand does not protrude from any side of the housing in a state in which the stand is attached to the base.
Patent NZ-626583-A (NZ)
Title: Process for the synthesis of highly pure cationic surfactant products
Inventor: MEHTA DILIP S
IPC: C07C231/02
Filed: 2012-05-04
Abstract: Disclosed herein is a process for the synthesis of highly pure cationic surfactant products by eliminating or reducing impurities generation. The process comprises the use of a non-hydrolytic or nearly non-hydrolytic reaction medium involving mono or biphasic reaction system with fatty acid halide wherein the fatty acid is selected from C4 to C20 and wherein the pH is between about 7.5 to about 8.5 and the said process having no pH hot spots.
Patent NZ-629884-A (NZ)
Title: Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
Inventor: KLOPFER KEVIN
IPC: C07D487/04
Filed: 2014-09-03
Abstract: Provided herein are solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer such as fumaric acid, benzoic acid, gentisic acid or maleic acid. Pharmaceutical compositions comprising such solid forms (e.g., cocrystals) and methods of use for treating, preventing, and managing various disorders are also provided herein, particularly with regard to reducing tumour load in cancer.
Patent NZ-631614-A (NZ)
Title: Genetically modified non-human animals and methods of use thereof
Inventor: MURPHY ANDREW J
IPC: C07K14/54
Filed: 2013-11-05
Abstract: Disclosed is a genetically modified non-human animal that comprises: a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter, and at least one additional nucleic acid selected from the group consisting of: i) a nucleic acid encoding human SIRPa operably linked to a SIRPa promoter; ii) a nucleic acid encoding human M-CSF operably linked to a M-CSF promoter; iii) a nucleic acid encoding human IL-3 operably linked to an IL-3 promoter; iv) a nucleic acid encoding human GM-CSF operably linked to a GM-CSF promoter; and v) a nucleic acid encoding human TPO operably linked to a TPO promoter. Also disclosed is a method of generating an animal model of human B cell development and function by transplanting a population of human hematopoietic cells into a genetically modified non-human animal that is immunodeficient and comprises a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter, wherein the animal expresses human IL-6 and does not express non-human animal IL-6.
Patent NZ-707490-A (NZ)
Title: Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
Inventor: HOWARD PHILIP WILSON
IPC: C07K16/30
Filed: 2013-10-11
Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile N10 protecting group in the form of a linker to an antibody, wherein the antibody is an antibody that binds to CD22, the antibody comprising a VH domain paired with a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2. The drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to 8. The present invention is suitable for use in providing a PBD compound to a preferred site in a subject. The conjugate allows the release of an active PBD compound that does not retain any part of the linker.